(PHAS) –
-
Form 8-K PhaseBio Pharmaceuticals For: Dec 20
-
Form 25-NSE PhaseBio Pharmaceuticals Filed by: Nasdaq Stock Market LLC
-
Form 8-K PhaseBio Pharmaceuticals For: Nov 28
-
PhaseBio Pharmaceuticals Inc. (PHAS) Announces CFO Resignation
-
Form 8-K PhaseBio Pharmaceuticals For: Nov 21
-
Form NT 10-Q PhaseBio Pharmaceuticals For: Sep 30
-
Form 8-K PhaseBio Pharmaceuticals For: Nov 04
-
Form SC 13D/A PhaseBio Pharmaceuticals Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Form 8-K PhaseBio Pharmaceuticals For: Oct 25
-
Form 4 PhaseBio Pharmaceuticals For: Oct 25 Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Cowen Downgrades PhaseBio Pharmaceuticals Inc. (PHAS) to Market Perform
-
PhaseBio Pharmaceuticals Inc. (PHAS) Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code
-
Form 8-K PhaseBio Pharmaceuticals For: Oct 23
-
PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code
-
Form 8-K PhaseBio Pharmaceuticals For: Oct 03
-
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.88%
-
UPDATE: Stifel Downgrades PhaseBio Pharmaceuticals Inc. (PHAS) to Hold
-
Needham & Company Downgrades PhaseBio Pharmaceuticals Inc. (PHAS) to Hold
-
William Blair Downgrades PhaseBio Pharmaceuticals Inc. (PHAS) to Market Perform
-
Form 8-K PhaseBio Pharmaceuticals For: Sep 21
-
Form 10-Q PhaseBio Pharmaceuticals For: Jun 30
-
Form 8-K PhaseBio Pharmaceuticals For: Aug 12
-
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
-
Form 8-K PhaseBio Pharmaceuticals For: Aug 04
-
Form SC 13G/A PhaseBio Pharmaceuticals Filed by: MAI Capital Management
-
Form 8-K PhaseBio Pharmaceuticals For: Jun 29
-
Form 4/A PhaseBio Pharmaceuticals For: May 19 Filed by: Humphries William D.
-
Form 4 PhaseBio Pharmaceuticals For: May 20 Filed by: Arnold Susan Elizabeth
-
Form 4 PhaseBio Pharmaceuticals For: May 20 Filed by: Mow Jonathan P
-
Form 4 PhaseBio Pharmaceuticals For: May 20 Filed by: Hanson Kristopher
-
Form 4 PhaseBio Pharmaceuticals For: May 20 Filed by: Burkhardt Glen
-
Form 4 PhaseBio Pharmaceuticals For: May 20 Filed by: Birchall Jonathan
-
Form 4 PhaseBio Pharmaceuticals For: May 20 Filed by: Sharp John P
-
Form 4/A PhaseBio Pharmaceuticals For: Aug 18 Filed by: Hutson Nancy J
-
Form 4 PhaseBio Pharmaceuticals For: May 19 Filed by: Humphries William D.
-
Form 4 PhaseBio Pharmaceuticals For: May 19 Filed by: Hutson Nancy J
-
Form 4 PhaseBio Pharmaceuticals For: May 19 Filed by: Thorp Clay
-
Form 4 PhaseBio Pharmaceuticals For: May 19 Filed by: Sapir Alex
-
Form 4 PhaseBio Pharmaceuticals For: May 19 Filed by: Loewy Caroline M
-
Form 4 PhaseBio Pharmaceuticals For: May 19 Filed by: van den Broek Richard
-
Form 4 PhaseBio Pharmaceuticals For: May 19 Filed by: HARRIGAN EDMUND
-
Form 8-K PhaseBio Pharmaceuticals For: May 19
-
Form 8-K PhaseBio Pharmaceuticals For: May 16
-
Form 10-Q PhaseBio Pharmaceuticals For: Mar 31
-
PhaseBio Pharmaceuticals Inc. (PHAS) Reports Successful Pre-BLA Meeting with the FDA for Bentracimab
-
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
-
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
-
Form DEF 14A PhaseBio Pharmaceuticals For: Apr 22
-
PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference
-
Form 8-K PhaseBio Pharmaceuticals For: Apr 04
Back to PHAS Stock Lookup